儿童型低级别胶质瘤药物化疗及靶向治疗进展  

Research advances on chemotherapy and targeted therapy of pediatric⁃type low⁃grade glioma

作　　者：盖菁菁[1] 孔晨晨 赵传 张俊平[1] GE Jing-jing;KONG Chen-chen;ZHAO Chuan;ZHANG Jun-ping(Department of Neuro-oncology,Sanbo Brain Hospital,Capital Medical University,Beijing 100093,China)

机构地区：[1]首都医科大学三博脑科医院神经肿瘤化疗中心,北京100093

出　　处：《中国现代神经疾病杂志》2024年第9期706-711,共6页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：北京市海淀区卫生健康发展科研培育计划项目(项目编号:HP2021-19-50802);首都卫生发展科研专项(项目编号:首发2022-2-8012)。

摘　　要：儿童型低级别胶质瘤是儿童最常见的中枢神经系统肿瘤,大多数呈非侵袭性,预后较好。手术全切除是重要的预后影响因素,可达到长期生存。然而对于位于脑干、视觉传导通路等脑深部结构的肿瘤,无法手术全切除,药物化疗是临床症状恶化或影像学进展时的首选辅助治疗方法;近年除传统药物化疗外,靶向治疗药物的研发和应用也取得显著进展。本文综述儿童型低级别胶质瘤药物化疗及靶向治疗进展及所面临的挑战,以指导临床实践。Pediatric⁃type low⁃grade glioma(pLGG)is the most common central nervous system tumor in children,and most pLGG exhibits non⁃invasive clinical behavior with a good prognosis.Total surgical resection is an important prognostic factor,and patients can achieve long⁃term survival after total tumor resection.However,tumors in deep location such as brain stem and optic pathway cannot be completely removed by surgery.Chemotherapy is the first choice of adjuvant treatment when the clinical symptoms of pLGG worsen or imaging progress.In recent years,in addition to traditional chemotherapy,the development and application of targeted therapy drugs have also made great progress.This article reviews the research progress and challenges of chemotherapy and targeted therapy of pLGG,in order to provide guidance for clinical practice.

关 键 词：神经胶质瘤 抗肿瘤联合化疗方案 血管生成抑制剂 分子靶向治疗 儿童 综述 

分 类 号：R739.41[医药卫生—肿瘤]